206
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

M-polynomial and Correlated Topological Indices of Antiviral Drug Molnupiravir Used as a Therapy for COVID-19

ORCID Icon, ORCID Icon & ORCID Icon
Pages 7027-7041 | Received 29 Nov 2021, Accepted 21 Sep 2022, Published online: 13 Oct 2022
 

Abstract

The coronavirus pandemic is an unending global epidemic of coronavirus disease 2019 (commonly known as, COVID-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2) that was first reported in Wuhan city of China at the end of the year 2019. Unfortunately, there was no oral antiviral drug for the treatment of this pandemic, which was urgently needed. Recently, after the phase 3 trial, researchers have reported the tolerability, safety profile and antiviral efficacy of Molnupiravir in the treatment of COVID-19. Topological indices are used to determine different physico-chemical, pharmaceutical and biological attributes of a molecular graph. In the current study, we depict the two-dimensional graph structure of the hydrogen-suppressed Molnupiravir. We calculate the values of some well-known degree-based topological indices for Molnupiravir drug by their standard definitions and alternatively by using M-polynomial approach which is more compact and appropriate. Among these indices, we obtain that the augmented Zagreb and modified second Zagreb indices have maximum and minimum values, respectively. Additionally, we geometrically represent the topological indices in increasing order and surface nature of the M-polynomial. The results obtained can help the researchers to study the pharmacokinetic properties of the newly developed drugs used in the treatment of COVID-19.

Acknowledgements

We sincerely thank the anonymous referees for the thorough reviews of this article and for their valuable suggestions and comments which have helped us to improve the quality of the article. Moreover, the second author is grateful to Banaras Hindu University (BHU), Varanasi for the financial support of the BHU-fellowship.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The second author received fellowship from BHU.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.